Maximizing Trial Value in Resource-Constrained Biotechs. S2. E5. скачать в хорошем качестве

Maximizing Trial Value in Resource-Constrained Biotechs. S2. E5.

In this episode of the @Drivin the Business of Science podcast, host Keith Parent, CEO of ‪@courtsquaregroup‬, speaks with Nathalie Riebel, CEO and founder of Oncospire ConsultantsTM, a consultancy specializing in small biotechs. Nathalie points to the $80 billion pharma outsourcing market and the performance and quality challenges that accompany it. The data consistently shows that this massive transfer of work is plagued by delays, quality failures, sponsor dissatisfaction, and governance gaps that remain stubbornly unresolved. The conversation emphasizes the need for small biotechs to effectively manage vendors and drive results. Oncospire’s "Clinical Momentum Method" helps companies to streamline processes and reduce oversight time. Oncospire provides packages for CRO selection, gap assessment (Critical Path Visibility Assessment), and operational improvements, aiming to save small biotechs time and money in the management of their full-service CROs and vendors.